Similarly, treatment with BRAF inhibitors has been shown to activate protective autophagy via the AMP-activated protein kinase–Unc-51-like autophagy activating kinase 1 axis (AMPK–ULK1 axis), thereby contributing to drug resistance in BRAF-mutant thyroid cancers[45]. This evidence concerns the gene BRAF and thyroid cancer.